Interstitial lung diseases (ILDs) are a heterogeneous group of conditions characterized by inflammation and fibrosis of the lung interstitium. They represent a significant diagnostic and therapeutic challenge in pulmonary medicine due to their complex pathophysiology and variable clinical presentation.
ILDs are primarily disorders of the lung interstitium, involving the alveolar epithelium, pulmonary capillary endothelium, basement membrane, perivascular and perilymphatic tissues. Inflammatory and immune responses lead to tissue damage, fibroblast proliferation, and extracellular matrix deposition, resulting in irreversible lung fibrosis and impaired gas exchange.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal inspiratory crackles and finger clubbing. The disease progression varies widely, from slow deterioration over years to a rapid decline within months.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs, allowing detailed visualization of the lung parenchyma. Pulmonary function tests reveal a restrictive pattern with reduced lung volumes and diffusing capacity. Bronchoalveolar lavage and surgical lung biopsy may be required in certain cases for definitive diagnosis.
Management of ILDs is multifaceted, involving pharmacological and non-pharmacological interventions. Corticosteroids and immunosuppressive agents are the mainstay of treatment for most ILDs. Antifibrotic agents have shown promise in idiopathic pulmonary fibrosis. Lung transplantation may be considered in advanced stages. Patient education, pulmonary rehabilitation, and palliative care play crucial roles in improving quality of life.
Understanding the complex nature of ILDs is crucial for timely diagnosis and appropriate management. Increased awareness about these conditions among healthcare professionals can significantly improve patient outcomes. Continued research is needed to further elucidate the pathophysiology of ILDs and develop more effective therapeutic strategies.
1.
Race, Geography Linked to Gaps in Prostate Cancer Care
2.
Sports for girls are frequently abandoned due to uniform issues.
3.
According to the Lancet, having cancer and VTE at the same time increases mortality risk.
4.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Hematopoietic Clonal Competition in Blood Disorders
2.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
3.
Developmental Iron Biology Beyond Infancy: Mechanisms, Clinical Implications, and Emerging Directions
4.
Next-Generation Bone Marrow Harvest Technologies
5.
Strategic Applications in Hematology in Clinical Decision-Making
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Understanding the Common Causes of Anemia
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation